|CellProthera is the first company having conducted successful proof of principle study with autologous CD34+ stem cells to repair myocardial tissue after acute myocardial infarct (AMI). The clinical outcome indicated an excellent safety profile associated with outstanding clinical benefits. The innovative approach developed by CellProthera is viewed by experts as one of the most effective to treat AMI and prevent secondary congestive heart failure (CHF).
||This “rupture” therapy has been assessed in a preliminary Proof of Concept clinical trial. This represents a unique alternative to cardiac transplant and can be a complement and/or a substitute for existing therapies like coronary bypass surgery and stenting.
CellProthera is in clinical phase, currently conducting an international clinical trial phase I/IIB including 44 European patients and about to start a supplementary trial in Singapore. Next will follow a phase III in both Europe and North America.